XEND-0501 is under clinical development by Pila Pharma and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XEND-0501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XEND-0501 overview
XEND-0501 is under development for the treatment of type 2 diabetes, erythromelalgia. The drug candidate is administered orally. It is a small molecule ion channel modulator which targets TRPV1. The drug candidate was also under development for overactive bladder and prevention of cough in patients with chronic idiopathic cough and chronic obstructive pulmonary disease (COPD).
Pila Pharma overview
Pila Pharma is a clinical stage pharmaceutical company that develops novel therapeutics for the treatment of diabetes. The company develops a novel type of oral anti-diabetic agent, and a TRPV1 antagonist for the treatment of diabetes. Its oral anti-diabetic agent controls bodyweight gain and hyperglycemia in type 2 diabetes. Pila Pharma owns patents for treating diabetes and obesity with antagonists of the TRPV1 receptor. The company’s TRPV1 target finds application in the areas of inflammatory diseases, cardiovascular diseases, pain and diabetes. It also develops clinical development candidate XEN-D0501. Pila Pharma is headquartered in Malmo, Sweden.
For a complete picture of XEND-0501’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
